Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Roxadustat

            Therapeutic Area: Hematology Product Name: Evrenzo

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: FibroGen, Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 27, 2020

            Details:

            The MHLW approval of EVRENZO marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human Fibrinogen,Thrombin

            Therapeutic Area: Hematology Product Name: TachoSil

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Corza

            Deal Size: $427.0 million Upfront Cash: 427.0 million

            Deal Type: Divestment September 16, 2020

            Details:

            Under the terms of the agreement, upon close, Corza Health will acquire the assets and licenses that support the development and commercialization of TachoSil®, while Takeda will maintain ownership of the manufacturing facility in Linz, Austria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Human fibrinogen,Thrombin

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Johnson & Johnson

            Deal Size: $400.0 million Upfront Cash: Undisclosed

            Deal Type: Termination April 10, 2020

            Details:

            In late March, EU antitrust regulators had expressed concern about the deal and opened a full investigation into it.